We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| UroGen Pharma Ltd | NASDAQ:URGN | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.11 | -0.65% | 16.86 | 16.91 | 16.92 | 17.248 | 16.78 | 17.04 | 308,758 | 20:50:00 |
From Jun 2023 to Jun 2024
By Sabela Ojea
Shares of UroGen Pharma surged on Thursday after the biotechnology company said Phase 3 trials for its bladder cancer investigational treatment UGN-102 are fully enrolled.
The stock was up 49% to $13.37 at 11:18 a.m. ET. The shares have jumped 62% in the past 12 months.
The company said completing enrollment for the study is a major milestone that brings them one step closer validation of the medication for low-grade intermediate-risk nonmuscle-invasive bladder cancer.
UroGen expects to submit a New Drug Application with the Food and Drug Administration for the treatment UGN-102 in 2024.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
July 27, 2023 11:51 ET (15:51 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year UroGen Pharma Chart |
1 Month UroGen Pharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
